154 related articles for article (PubMed ID: 20370379)
1. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy.
Barnett AH
Curr Med Res Opin; 2010 Jun; 26(6):1333-42. PubMed ID: 20370379
[TBL] [Abstract][Full Text] [Related]
2. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
Halimi S; Raccah D; Schweizer A; Dejager S
Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
4. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
5. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
Baxter MA
Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
[TBL] [Abstract][Full Text] [Related]
6. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
Holstein A; Egberts EH
Exp Clin Endocrinol Diabetes; 2003 Oct; 111(7):405-14. PubMed ID: 14614647
[TBL] [Abstract][Full Text] [Related]
7. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
8. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
Raskin P
Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
[TBL] [Abstract][Full Text] [Related]
9. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.
Stewart MW; Cirkel DT; Furuseth K; Donaldson J; Biswas N; Starkie MG; Phenekos C; Hamann A
Diabet Med; 2006 Oct; 23(10):1069-78. PubMed ID: 16978370
[TBL] [Abstract][Full Text] [Related]
10. Impact of therapeutic advances on hypoglycaemia in type 2 diabetes.
Boyle PJ; Zrebiec J
Diabetes Metab Res Rev; 2008; 24(4):257-85. PubMed ID: 18232062
[TBL] [Abstract][Full Text] [Related]
11. Insulin therapy in type 2 diabetes: what is the evidence?
van Avendonk MJ; Rutten GE
Diabetes Obes Metab; 2009 May; 11(5):415-32. PubMed ID: 19175375
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
13. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes.
Barnett AH; Cradock S; Fisher M; Hall G; Hughes E; Middleton A
Int J Clin Pract; 2010 Jul; 64(8):1121-9. PubMed ID: 20236369
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
Mathur SK; Bansal A; Khan ZY
J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes?
Frier BM
Int J Clin Pract Suppl; 2002 Jul; (129):12-9. PubMed ID: 12166599
[TBL] [Abstract][Full Text] [Related]
16. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
Yki-Järvinen H
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
[TBL] [Abstract][Full Text] [Related]
18. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
Panina G
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():32-9. PubMed ID: 17877545
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
20. Severe hypoglycaemia in type 1 diabetes: impact of the renin-angiotensin system and other risk factors.
Pedersen-Bjergaard U
Dan Med Bull; 2009 Nov; 56(4):193-207. PubMed ID: 19939337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
